Premium
Impact of self‐administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider
Author(s) -
Selleslag Dominik,
Bird Robert,
Altomare Ivy,
Giagounidis Aristoteles,
Janssens Ann,
Pabinger Ingrid,
Pullarkat Vinod,
Wei Helen,
Kreuzbauer Georg
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12415
Subject(s) - romiplostim , medicine , discontinuation , adverse effect , platelet , immune thrombocytopenia , post hoc analysis , thrombopoietin , genetics , stem cell , haematopoiesis , biology
Objective This post hoc analysis evaluated romiplostim self‐administration ( SA group) vs. romiplostim administration by a healthcare provider in a clinical setting ( HCP group) in patients with chronic immune thrombocytopenia ( ITP ). Methods Outcomes from 3 ITP trials allowing self‐administration in patients achieving a stable romiplostim dose for ≥3 consecutive weeks were compared. Evaluations were conducted for 12‐wk treatment intervals. Efficacy endpoints included percentage of patients and weeks with platelets within the target range of 50–200 × 10 9 /L and safety. Results Baseline characteristics suggested less severe disease in the SA groups ( n = 563) than in the HCP groups ( n = 241). The SA groups had greater proportions of patients achieving the target platelet range (55–58% vs. 40–52%) and greater proportions of weeks with a platelet response (75–88% vs. 47–76%) than the HCP groups. The rate of romiplostim discontinuation was twofold to fivefold lower in the SA groups than in the HCP groups. Rates of duration‐adjusted adverse events ( AE s), serious AE s and treatment‐related AE s were also lower in the SA groups. Conclusions In conclusion, in adults with ITP receiving romiplostim, self‐administration was comparable to healthcare provider administration in terms of efficacy and safety profiles, suggesting that self‐administration of romiplostim is a feasible option for certain patients with ITP .